CC Chemours Co
Chemicals & Allied Products · NYSE · SEC CIK 1627223 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.1%
TTM net income YoY56.0%
TTM EPS YoY56.2%
Revenue 3-yr CAGR-1.2%
Net income 3-yr CAGR—
Margins
Gross margin15.2%
Operating margin—
Net margin-2.6%
FCF margin3.6%
EBITDA margin—
Returns
ROE-71.8%
ROA-2.1%
ROIC (approx.)—
Asset turnover0.79x
Leverage & solvency
Liabilities / assets97.9%
Debt / equity24.73x
Current ratio1.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.60x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.81B | $5.78B |
| Cost of revenue | $4.91B | $4.64B |
| Gross profit | $902.00M | $1.14B |
| R&D expense | $108.00M | $109.00M |
| SG&A expense | $799.00M | $598.00M |
| Interest expense | $269.00M | $263.00M |
| Pretax income | -$277.00M | $106.00M |
| Income tax | $109.00M | $37.00M |
| Net income | -$386.00M | $69.00M |
| EPS (basic) | -2.57 | 0.46 |
| EPS (diluted) | -2.57 | 0.46 |
| Dividends declared per share | 0.51 | 1.00 |
| Weighted avg. shares (diluted) | 150.24M | 150.17M |
| Balance sheet | ||
| Cash & equivalents | $670.00M | $763.00M |
| Receivables | $562.00M | $619.00M |
| Inventory | $1.57B | $1.46B |
| Current assets | $3.00B | $3.02B |
| PP&E, net | $3.08B | $3.19B |
| Goodwill | $46.00M | $46.00M |
| Intangibles | $2.00M | $3.00M |
| Total assets | $7.38B | $7.51B |
| Current liabilities | $1.69B | $1.82B |
| Short-term debt | $42.00M | $54.00M |
| Long-term debt | $4.10B | $4.06B |
| Total debt | $4.14B | $4.11B |
| Total liabilities | $7.13B | $6.94B |
| Shareholders' equity | $250.00M | $571.00M |
| Net debt | $3.47B | $3.35B |
| Shares outstanding | 149.89M | 149.43M |
| Cash flow statement | ||
| Operating cash flow | $264.00M | -$633.00M |
| Capital expenditure | $213.00M | $360.00M |
| Free cash flow | $51.00M | -$993.00M |
| Investing cash flow | -$206.00M | -$353.00M |
| Financing cash flow | -$126.00M | -$36.00M |
| Depreciation & amortization | $340.00M | $292.00M |
| Stock-based compensation | $21.00M | $15.00M |
| Dividends paid | $78.00M | $148.00M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.